Trial Profile
Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2020
Price :
$35
*
At a glance
- Drugs Voxilaprevir (Primary) ; Sofosbuvir/velpatasvir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 09 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2015 Sofosbuvir/GS-5816 fixed dose combination was introduced in the protocol and treatment arms have been changed from 4 to 5 as reported by ClinicalTrials.gov
- 11 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov